Atazanavir Sulfate/Cobicistat

硫酸阿扎那韦/考比司他

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtazanavir Sulfate/Cobicistat
Drug Alias Name考西司他硫酸阿扎那韦Cobicistat/Atazanavir SulfateAtazanavir Sulfate and Cobicistat硫酸阿扎那韦考西司他Cobicistat and Atazanavir Sulfate +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsCytochrome P450 3A inhibitors
TargetsCytochrome P450 3AHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/01/29
Country/TerritoryUnited StatesEU
CombinationsYes Atazanavir SulfateCobicistat
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Pharma EeigBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR
Related LinksN/A